Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases
- PMID: 17414097
- DOI: 10.1097/01.pas.0000213393.57322.c7
Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases
Abstract
Inflammatory myofibroblastic tumor (IMT) is a neoplasm of intermediate biologic potential. In this study, we report a subset of IMTs with histologic atypia and/or clinical aggressiveness that were analyzed for clinicopathologic features, outcome, and immunohistochemical expression of anaplastic lymphoma kinase (ALK) and other markers to identify potential pathologic prognostic features. Fifty-nine IMTs with classic morphology (5 cases), atypical histologic features (21 cases), local recurrence (27 cases), and/or metastasis (6 cases) were studied. Immunohistochemistry was performed for ALK1 and other markers (Mib-1, c-Myc, cyclin D1, caspase 3, Bcl-2, Mcl-1, survivin, p27, CD56, p53, MDM-2) using standard techniques. The 59 IMTs had an age at diagnosis ranging from 3 weeks to 74 years (mean 13.2 y, median 11 y, 44% in the first decade). The mean tumor size was 7.8 cm. Sites included the abdomen or pelvis in 64%, lung in 22%, head and neck in 8%, and extremities in 5%. The follow-up ranged from 3 months to 11 years, with a mean of 3.6 years and a median of 3 years. Thirty-three patients had local recurrences, including 13 with multiple local recurrences and 6 patients with both local recurrences and distant metastases. Six patients died of disease, 5 with local recurrences, and 1 with distant metastases. Histologic evolution to a more pleomorphic cellular, spindled, polygonal, or round cell morphologic pattern was observed in 7 cases. Abdominal and pelvic IMTs had a recurrence rate of 85%. Recurrent and metastatic IMTs were larger, with mean diameters of 8.7 and 11 cm, respectively. Cytoplasmic ALK reactivity was seen in 56%. ALK-negative IMTs occurred in older patients (mean age 20.1) years and had greater nuclear pleomorphism, atypia, and atypical mitoses. All 6 metastatic IMTs were ALK-negative. Nuclear expression of p53 was detected in 80% of IMTs overall, but in only 25% of the metastatic subset. There were no significant differences among the subgroups for c-Myc, cyclin D1, MDM-2, Mcl-1, Bcl-2, CD56, p27, caspase 3, or survivin expression. In conclusion, among these 59 IMTs, ALK reactivity was associated with local recurrence, but not distant metastasis, which was confined to ALK-negative lesions. Absent ALK expression was associated with a higher age overall, subtle histologic differences, and death from disease or distant metastases (in a younger subset). Other proliferative, apoptotic, and prognostic markers did not correlate well with morphology or outcome. Thus, ALK reactivity may be a favorable prognostic indicator in IMT and abdominopelvic IMTs recur more frequently.
Similar articles
-
Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.Am J Surg Pathol. 2011 Jan;35(1):135-44. doi: 10.1097/PAS.0b013e318200cfd5. Am J Surg Pathol. 2011. PMID: 21164297
-
Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma.Am J Surg Pathol. 2006 Dec;30(12):1502-12. doi: 10.1097/01.pas.0000213280.35413.1b. Am J Surg Pathol. 2006. PMID: 17122505
-
Inflammatory myofibroblastic tumor and low-grade myofibroblastic sarcoma: a comparative study of clinicopathologic features and further observations on the immunohistochemical profile of myofibroblasts.Hum Pathol. 2008 Jun;39(6):846-56. doi: 10.1016/j.humpath.2007.10.010. Epub 2008 Apr 8. Hum Pathol. 2008. PMID: 18400254
-
Low-grade abdominopelvic sarcoma with myofibroblastic features (low-grade myofibroblastic sarcoma): clinicopathological, immunohistochemical, molecular genetic and ultrastructural study of two cases with literature review.J Clin Pathol. 2008 Mar;61(3):301-6. doi: 10.1136/jcp.2007.048561. Epub 2007 May 18. J Clin Pathol. 2008. PMID: 17513510 Review.
-
Head and neck inflammatory myofibroblastic tumor (IMT): evaluation of clinicopathologic and prognostic features.Oral Oncol. 2012 Feb;48(2):141-8. doi: 10.1016/j.oraloncology.2011.09.004. Epub 2011 Oct 19. Oral Oncol. 2012. PMID: 22014665 Review.
Cited by
-
Locally Advanced Inflammatory Myofibroblastic Tumor Treated With Targeted Therapy: A Case Report and Literature Review.Cureus. 2022 Jul 25;14(7):e27223. doi: 10.7759/cureus.27223. eCollection 2022 Jul. Cureus. 2022. PMID: 36035049 Free PMC article.
-
Inflammatory myofibroblastic tumor of the colon with an unusual presentation of intestinal intussusception.European J Pediatr Surg Rep. 2014 Jun;2(1):54-7. doi: 10.1055/s-0034-1370774. Epub 2014 Apr 4. European J Pediatr Surg Rep. 2014. PMID: 25755972 Free PMC article.
-
Epithelioid inflammatory myofibroblastic sarcoma: a clinicopathological, immunohistochemical and molecular cytogenetic analysis of five additional cases and review of the literature.Diagn Pathol. 2016 Jul 27;11(1):67. doi: 10.1186/s13000-016-0517-z. Diagn Pathol. 2016. PMID: 27460384 Free PMC article. Review.
-
Retroperitoneal Sarcomas: An Update on the Diagnostic Pathology Approach.Diagnostics (Basel). 2020 Aug 27;10(9):642. doi: 10.3390/diagnostics10090642. Diagnostics (Basel). 2020. PMID: 32867125 Free PMC article. Review.
-
Follow-Up Imaging of Inflammatory Myofibroblastic Tumor of the Uterus and Its Spontaneous Regression.Iran J Radiol. 2016 Jan 30;13(1):e12991. doi: 10.5812/iranjradiol.12991. eCollection 2016 Jan. Iran J Radiol. 2016. PMID: 27110328 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous